Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweight and raises the price target from $6 to $8.
Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweight and raises the price target from $6 to $8.